MARKETS
Earnings

CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate

Aug 10, 2026 · 06:24 PM ET· updated 53m ago

Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of $(0.30) per share from

Share
Why It Matters

Insight Molecular lost less money than people expected, which is good, but made way less money than expected, which is bad. When a company misses on sales this badly, that's usually a bigger worry than beating on losses.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.